KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Committee for Orphan Medicinal Products (COMP) of the ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Decision highlights the promise of BGB-16673, an investigational and potentially first-in-class BTK degrader designed to overcome resistance and deepen responses in B-cell malignancies ...

The designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the most undervalued quality stocks to buy according to hedge funds. On July 25, the European Medicines Agency’s Committee for Medicinal Products for Human ...

The European Medicines Agency’s human medicines committee has recommended that BeOne Medicines’ Tevimbra (tislelizumab) be ...

A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

Taiwan region became the last region across all Everest’s territories to grant full approval for NEFECON (R), together with Mainland China, Singapore, Macao SAR, Hong Kong SAR and South Korea. This ...

Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 Provided by GlobeNewswire Jul 21, 2025, 5:00:00 AM ...

LONDON -- The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus' transmission.